Thu, November 17, 2022 – Evogene (EVGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this agricultural company would post a loss of $0.18 per share when it actually produced a loss of $0.21, delivering a surprise of -16.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Evogene , which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $0.47 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 79.23%. This compares to year-ago revenues of $0.15 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Evogene shares have lost about 55.3% since the beginning of the year versus the S&P 500’s decline of -16.9%.

What’s Next for Evogene?

While Evogene has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Evogene: mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.20 on $0.88 million in revenues for the coming quarter and -$0.76 on $1.69 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Avid Bioservices (CDMO), has yet to report results for the quarter ended October 2022.

This contract manufacturer is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of -110%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Avid Bioservices’ revenues are expected to be $31 million, up 18.7% from the year-ago quarter.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.